The future of KRAS-targeted therapies lies in a multi-faceted approach. This includes the development of inhibitors targeting other KRAS mutations, such as G12D and G12V, as well as exploring combination therapies that target both KRAS and its downstream effectors. Additionally, researchers are investigating the use of immunotherapy in combination with KRAS-targeted treatments to enhance anti-tumor responses. Ongoing research and clinical trials will be crucial in determining the most effective strategies for treating KRAS-mutant cancers.
